Minerva Biotechnologies

Minerva Biotechnologies is developing therapies for curing cancers and commercializing core technology that will enable next generation stem cell therapies. Both flow from Minerva’s fundamental discovery that both cancer cell and stem cell growth are mediated by the same two molecules: the growth factor NME-p and the growth factor receptor MUC1*. -Cancer Therapeutics- Minerva discovered that cancer cells are healthy cells that are being reprogrammed back to a stem cell state. We can reverse the reprogramming and make cancer cells differentiate so that cancer growth is turned off. This is a novel approach to curing cancer. We have 3 anti-cancer therapeutics in our pipeline. -Regenerative Medicine- Minerva is the first company to generate human naïve state pluripotent stem cells using a single, naturally occurring human stem cell growth factor. These earlier stem cells have a clean slate, and are more easily directed to develop into functional mature cells, which could be used for transplant.